Suzanne V Arnold1, Yang Lei2, Matthew R Reynolds2, Elizabeth A Magnuson2, Rakesh M Suri2, E Murat Tuzcu2, John L Petersen2, Pamela S Douglas2, Lars G Svensson2, Hemal Gada2, Vinod H Thourani2, Susheel K Kodali2, Michael J Mack2, Martin B Leon2, David J Cohen2. 1. From the Saint Luke's Mid America Heart Institute, Kansas City, MO (S.V.A., Y.L., E.A.M., D.J.C.); University of Missouri-Kansas City (S.V.A., E.A.M., D.J.C.); Harvard Clinical Research Institute, Boston, MA (M.R.R.); Mayo Clinic, Rochester, MN (R.M.S.); Cleveland Clinic Foundation, OH (E.M.T., L.G.S.); Swedish Medical Center, Seattle, WA (J.L.P.); Duke University, Durham, NC (P.S.D.); Columbia-Presbyterian Hospital, New York, NY (H.G., S.K.K., M.B.L.); Emory University School of Medicine, Atlanta, GA (V.H.T.); and Baylor Healthcare System, Plano, TX (M.J.M.). suz.v.arnold@gmail.com. 2. From the Saint Luke's Mid America Heart Institute, Kansas City, MO (S.V.A., Y.L., E.A.M., D.J.C.); University of Missouri-Kansas City (S.V.A., E.A.M., D.J.C.); Harvard Clinical Research Institute, Boston, MA (M.R.R.); Mayo Clinic, Rochester, MN (R.M.S.); Cleveland Clinic Foundation, OH (E.M.T., L.G.S.); Swedish Medical Center, Seattle, WA (J.L.P.); Duke University, Durham, NC (P.S.D.); Columbia-Presbyterian Hospital, New York, NY (H.G., S.K.K., M.B.L.); Emory University School of Medicine, Atlanta, GA (V.H.T.); and Baylor Healthcare System, Plano, TX (M.J.M.).
Abstract
BACKGROUND: In patients with severe aortic stenosis, transcatheter aortic valve replacement (TAVR) improves survival when compared with nonsurgical therapy but with higher in-hospital and lifetime costs. Complications associated with TAVR may decrease with greater experience and improved devices, thereby reducing the overall cost of the procedure. Therefore, we sought to estimate the effect of periprocedural complications on in-hospital costs and length of stay of TAVR. METHODS AND RESULTS: Using detailed cost data from 406 TAVR patients enrolled in the Placement of Aortic Transcatheter Valve (PARTNER) I trial, we developed multivariable models to estimate the incremental cost and length of stay associated with specific periprocedural complications. Attributable costs and length of stay for each complication were calculated by multiplying the independent cost of each event by its frequency in the treatment group. Mean cost for the initial hospitalization was $79 619±40 570 ($50 891 excluding the valve); 49% of patients had ≥1 complication. Seven complications were independently associated with increased hospital costs, with major bleeding, arrhythmia, and death accounting for the largest attributable cost per patient. Renal failure and the need for repeat TAVR, although less frequent, were also associated with substantial incremental and attributable costs. Overall, complications accounted for $12 475 per patient in initial hospital costs and 2.4 days of hospitalization. CONCLUSIONS: In the PARTNER trial, periprocedural complications were frequent, costly, and accounted for ≈25% of non-implant-related hospital costs. Avoidance of complications should improve the cost-effectiveness of TAVR for inoperable and high-risk patients, but reductions in the cost of uncomplicated TAVR will also be necessary for optimal efficiency. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00530894.
RCT Entities:
BACKGROUND: In patients with severe aortic stenosis, transcatheter aortic valve replacement (TAVR) improves survival when compared with nonsurgical therapy but with higher in-hospital and lifetime costs. Complications associated with TAVR may decrease with greater experience and improved devices, thereby reducing the overall cost of the procedure. Therefore, we sought to estimate the effect of periprocedural complications on in-hospital costs and length of stay of TAVR. METHODS AND RESULTS: Using detailed cost data from 406 TAVR patients enrolled in the Placement of Aortic Transcatheter Valve (PARTNER) I trial, we developed multivariable models to estimate the incremental cost and length of stay associated with specific periprocedural complications. Attributable costs and length of stay for each complication were calculated by multiplying the independent cost of each event by its frequency in the treatment group. Mean cost for the initial hospitalization was $79 619±40 570 ($50 891 excluding the valve); 49% of patients had ≥1 complication. Seven complications were independently associated with increased hospital costs, with major bleeding, arrhythmia, and death accounting for the largest attributable cost per patient. Renal failure and the need for repeat TAVR, although less frequent, were also associated with substantial incremental and attributable costs. Overall, complications accounted for $12 475 per patient in initial hospital costs and 2.4 days of hospitalization. CONCLUSIONS: In the PARTNER trial, periprocedural complications were frequent, costly, and accounted for ≈25% of non-implant-related hospital costs. Avoidance of complications should improve the cost-effectiveness of TAVR for inoperable and high-risk patients, but reductions in the cost of uncomplicated TAVR will also be necessary for optimal efficiency. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00530894.
Authors: Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock Journal: N Engl J Med Date: 2010-09-22 Impact factor: 91.245
Authors: Matthew R Reynolds; Elizabeth A Magnuson; Kaijun Wang; Yang Lei; Katherine Vilain; Joshua Walczak; Susheel K Kodali; John M Lasala; William W O'Neill; Charles J Davidson; Craig R Smith; Martin B Leon; David J Cohen Journal: Circulation Date: 2012-02-03 Impact factor: 29.690
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Deborah A Taira; Todd B Seto; Richard Siegrist; Roberta Cosgrove; Ronna Berezin; David J Cohen Journal: Am Heart J Date: 2003-03 Impact factor: 4.749
Authors: Stefan Toggweiler; Ronen Gurvitch; Jonathon Leipsic; David A Wood; Alexander B Willson; Ronald K Binder; Anson Cheung; Jian Ye; John G Webb Journal: J Am Coll Cardiol Date: 2012-01-10 Impact factor: 24.094
Authors: A Pieter Kappetein; Stuart J Head; Philippe Généreux; Nicolo Piazza; Nicolas M van Mieghem; Eugene H Blackstone; Thomas G Brott; David J Cohen; Donald E Cutlip; Gerrit-Anne van Es; Rebecca T Hahn; Ajay J Kirtane; Mitchell W Krucoff; Susheel Kodali; Michael J Mack; Roxana Mehran; Josep Rodés-Cabau; Pascal Vranckx; John G Webb; Stephan Windecker; Patrick W Serruys; Martin B Leon Journal: J Am Coll Cardiol Date: 2012-10-09 Impact factor: 24.094
Authors: Philippe Généreux; Susheel K Kodali; Philip Green; Jean-Michel Paradis; Benoit Daneault; Garvey Rene; Irene Hueter; Isaac Georges; Ajay Kirtane; Rebecca T Hahn; Craig Smith; Martin B Leon; Mathew R Williams Journal: Am J Cardiol Date: 2012-10-04 Impact factor: 2.778
Authors: Todd M Dewey; Bruce Bowers; Vinod H Thourani; Vasilis Babaliaros; Craig R Smith; Martin B Leon; Lars G Svensson; E Murat Tuzcu; D Craig Miller; Paul S Teirstein; Jeffrey Tyner; David L Brown; Gregory P Fontana; Raj R Makkar; Mathew R Williams; Isaac George; Ajay J Kirtane; Joseph E Bavaria; Michael J Mack Journal: Ann Thorac Surg Date: 2013-08-20 Impact factor: 4.330
Authors: Alexander C Fanaroff; Pratik Manandhar; David R Holmes; David J Cohen; J Kevin Harrison; G Chad Hughes; Vinod H Thourani; Michael J Mack; Matthew W Sherwood; W Schuyler Jones; Sreekanth Vemulapalli Journal: Circ Cardiovasc Interv Date: 2017-10 Impact factor: 6.546
Authors: Lloyd M Felmly; Carlo N De Cecco; U Joseph Schoepf; Akos Varga-Szemes; Stefanie Mangold; Andrew D McQuiston; Sheldon E Litwin; Richard R Bayer; Thomas J Vogl; Julian L Wichmann Journal: Eur Radiol Date: 2016-08-23 Impact factor: 5.315
Authors: Suzanne V Arnold; Yiran Zhang; Suzanne J Baron; Thomas C McAndrew; Maria C Alu; Susheel K Kodali; Samir Kapadia; Vinod H Thourani; D Craig Miller; Michael J Mack; Martin B Leon; David J Cohen Journal: JACC Cardiovasc Interv Date: 2019-02-25 Impact factor: 11.195
Authors: Matthew R Reynolds; Yang Lei; Kaijun Wang; Khaja Chinnakondepalli; Katherine A Vilain; Elizabeth A Magnuson; Benjamin Z Galper; Christopher U Meduri; Suzanne V Arnold; Suzanne J Baron; Michael J Reardon; David H Adams; Jeffrey J Popma; David J Cohen Journal: J Am Coll Cardiol Date: 2016-01-05 Impact factor: 24.094
Authors: Matthew W Sherwood; Aakriti Gupta; Sreekanth Vemulapalli; Zhuokai Li; Jonathan Piccini; J Kevin Harrison; David Dai; Amit N Vora; Michael J Mack; David R Holmes; John S Rumsfeld; David J Cohen; Vinod H Thourani; Ajay J Kirtane; Eric D Peterson Journal: Circ Cardiovasc Interv Date: 2021-04-20 Impact factor: 6.546
Authors: Klaus Kaier; Frederike von Kampen; Hardy Baumbach; Constantin von Zur Mühlen; Philip Hehn; Werner Vach; Manfred Zehender; Christoph Bode; Jochen Reinöhl Journal: BMC Health Serv Res Date: 2017-07-11 Impact factor: 2.655
Authors: Stefan Stortecky; Giulio G Stefanini; Thomas Pilgrim; Dik Heg; Fabien Praz; Fabienne Luterbacher; Raffaele Piccolo; Ahmed A Khattab; Lorenz Räber; Bettina Langhammer; Christoph Huber; Bernhard Meier; Peter Jüni; Peter Wenaweser; Stephan Windecker Journal: J Am Heart Assoc Date: 2015-09-25 Impact factor: 5.501
Authors: Harindra C Wijeysundera; Lindsay Li; Vevien Braga; Nandhaa Pazhaniappan; Anar M Pardhan; Dana Lian; Aric Leeksma; Ben Peterson; Eric A Cohen; Anne Forsey; Kori J Kingsbury Journal: Open Heart Date: 2016-08-16